Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of “Reduce” by Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given a consensus rating of “Reduce” by the twelve brokerages that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $8.20.

A number of equities research analysts have issued reports on FULC shares. Leerink Partners downgraded Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price target for the company. in a research note on Tuesday, June 2nd. Piper Sandler cut shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research note on Tuesday, June 2nd. Jefferies Financial Group set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Tuesday, June 2nd. Cantor Fitzgerald cut shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Finally, HC Wainwright downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research report on Tuesday, June 2nd.

Fulcrum Therapeutics Price Performance

FULC stock opened at $3.89 on Tuesday. The company has a market cap of $296.81 million, a P/E ratio of -3.21 and a beta of 3.05. Fulcrum Therapeutics has a 1 year low of $2.83 and a 1 year high of $15.74. The stock’s fifty day moving average price is $3.73 and its 200-day moving average price is $5.93.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.10). As a group, analysts expect that Fulcrum Therapeutics will post -0.69 earnings per share for the current year.

Insider Activity

In other news, Director Alan Ezekowitz sold 18,000 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.65, for a total value of $65,700.00. Following the completion of the sale, the director directly owned 10,927 shares in the company, valued at $39,883.55. This represents a 62.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 7.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. AXQ Capital LP grew its holdings in Fulcrum Therapeutics by 269.7% during the second quarter. AXQ Capital LP now owns 81,483 shares of the company’s stock valued at $298,000 after purchasing an additional 59,440 shares during the period. Headlands Technologies LLC bought a new position in shares of Fulcrum Therapeutics in the second quarter worth about $328,000. Hsbc Holdings PLC lifted its position in shares of Fulcrum Therapeutics by 86.5% during the 2nd quarter. Hsbc Holdings PLC now owns 109,353 shares of the company’s stock valued at $426,000 after buying an additional 50,717 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Fulcrum Therapeutics by 140.4% during the 2nd quarter. Wellington Management Group LLP now owns 285,084 shares of the company’s stock valued at $1,043,000 after buying an additional 166,484 shares in the last quarter. Finally, Nantahala Capital Management LLC bought a new position in shares of Fulcrum Therapeutics during the 2nd quarter valued at approximately $20,038,646. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.